Semaglutide, liraglutide, and dulaglutide have all demonstrated modest systolic blood pressure reductions in clinical studies
Autointoxication and historical precursors of the microbiomegut-brain axis
Structural modifications such as acylation or targeted amino acid substitutions extend their stability and half-life, enabling convenient daily or even weekly dosing
The primary outcome was all-cause mortality, while secondary outcomes included: GERD complications esophageal cancer incidence PPI use The results revealed that GLP-1 RA users had a significantly lower risk of all-cause mortality (OR 0.18, 95% CI 0.130.25) and reduced odds of starting PPI therapy (OR 0.78, 95% CI 0.620.98)
[DOI] [PMC free article] [PubMed] [Google Scholar] 70.Yang A, Mottillo EP, Mladenovic-Lucas L, Zhou L, Granneman JG
Dungan K (2019): Amylin analogs for the treatment of diabetes mellitus